483 related articles for article (PubMed ID: 25735190)
1. Hematopoietic stem cell transplantation-associated thrombotic microangiopathy accompanied by renal arteriolar C4d deposition.
Sakamoto K; Imamura T; Osone S; Nishimura A; Nishida M; Ishida H; Hosoi H
Pediatr Transplant; 2015 Jun; 19(4):E97-100. PubMed ID: 25735190
[TBL] [Abstract][Full Text] [Related]
2. Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Laskin BL; Maisel J; Goebel J; Yin HJ; Luo G; Khoury JC; Davies SM; Jodele S
Transplantation; 2013 Jul; 96(2):217-23. PubMed ID: 23698598
[TBL] [Abstract][Full Text] [Related]
3. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
[TBL] [Abstract][Full Text] [Related]
4. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.
Schoettler M; Lehmann L; Li A; Ma C; Duncan C
Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820
[TBL] [Abstract][Full Text] [Related]
5. Renal thrombotic microangiopathy associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Mii A; Shimizu A; Kaneko T; Fujita E; Fukui M; Fujino T; Utsumi K; Yamaguchi H; Tajika K; Tsuchiya S; Iino Y; Katayama Y; Fukuda Y
Pathol Int; 2011 Sep; 61(9):518-27. PubMed ID: 21884301
[TBL] [Abstract][Full Text] [Related]
6. Renal thrombotic microangiopathy associated with chronic humoral graft versus host disease after hematopoietic stem cell transplantation.
Mii A; Shimizu A; Masuda Y; Fujino T; Kaneko T; Utsumi K; Arai T; Ishikawa A; Wakamatsu K; Tajika K; Iino Y; Katayama Y; Fukuda Y
Pathol Int; 2011 Jan; 61(1):34-41. PubMed ID: 21166941
[TBL] [Abstract][Full Text] [Related]
7. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Jodele S; Fukuda T; Vinks A; Mizuno K; Laskin BL; Goebel J; Dixon BP; Teusink A; Pluthero FG; Lu L; Licht C; Davies SM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):518-25. PubMed ID: 24370861
[TBL] [Abstract][Full Text] [Related]
8. Use of Eculizumab in Pediatric Patients with High-Risk Transplantation-Associated Thrombotic Microangiopathy: Outcomes and Risk Factors Associated with Response and Survival. A Retrospective Study on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
Benítez Carabante MI; Bueno D; Alonso García L; López Torija I; Marsal J; Fernandez Navarro JM; Uria Oficialdegui ML; Panesso M; Molina B; Beléndez Bieler C; Palomo P; Pérez Martínez A; Diaz-de-Heredia C
Transplant Cell Ther; 2024 Jun; 30(6):601.e1-601.e13. PubMed ID: 38521410
[TBL] [Abstract][Full Text] [Related]
9. Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy.
Chua JS; Baelde HJ; Zandbergen M; Wilhelmus S; van Es LA; de Fijter JW; Bruijn JA; Bajema IM; Cohen D
J Am Soc Nephrol; 2015 Sep; 26(9):2239-47. PubMed ID: 25573909
[TBL] [Abstract][Full Text] [Related]
10. Eculizumab and thrombotic microangiopathy after hematopoietic stem cell transplantation: A report on its efficacy and safety in two pediatric patients.
Genere L; Bacchetta J; Bertrand Y; Javouhey E; Cheikh N; Sellier-Leclerc AL
Arch Pediatr; 2018 Nov; 25(8):485-488. PubMed ID: 30340942
[TBL] [Abstract][Full Text] [Related]
11. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis.
Zhang R; Zhou M; Qi J; Miao W; Zhang Z; Wu D; Han Y
Front Immunol; 2020; 11():564647. PubMed ID: 33552043
[TBL] [Abstract][Full Text] [Related]
13. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.
Jodele S; Dandoy CE; Lane A; Laskin BL; Teusink-Cross A; Myers KC; Wallace G; Nelson A; Bleesing J; Chima RS; Hirsch R; Ryan TD; Benoit S; Mizuno K; Warren M; Davies SM
Blood; 2020 Mar; 135(13):1049-1057. PubMed ID: 31932840
[TBL] [Abstract][Full Text] [Related]
14. Early Increase in Complement Terminal Pathway Activation Marker sC5b-9 Is Predictive for the Development of Thrombotic Microangiopathy after Stem Cell Transplantation.
Horváth O; Kállay K; Csuka D; Mező B; Sinkovits G; Kassa C; Stréhn A; Csordás K; Sinkó J; Prohászka Z; Kriván G
Biol Blood Marrow Transplant; 2018 May; 24(5):989-996. PubMed ID: 29339271
[TBL] [Abstract][Full Text] [Related]
15. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
[TBL] [Abstract][Full Text] [Related]
16. The alternative complement pathway activation product Ba as a marker for transplant-associated thrombotic microangiopathy.
Sartain S; Shubert S; Wu MF; Wang T; Martinez C
Pediatr Blood Cancer; 2020 Mar; 67(3):e28070. PubMed ID: 31774252
[TBL] [Abstract][Full Text] [Related]
17. A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.
Jodele S; Laskin BL; Dandoy CE; Myers KC; El-Bietar J; Davies SM; Goebel J; Dixon BP
Blood Rev; 2015 May; 29(3):191-204. PubMed ID: 25483393
[TBL] [Abstract][Full Text] [Related]
18. A Heterozygous CFHR3-CFHR1 Gene Deletion in a Pediatric Patient With Transplant-associated Thrombotic Microangiopathy Who was Treated With Eculizumab.
Nozawa A; Ozeki M; Hori T; Kawamoto N; Hirayama M; Azuma E; Fukao T
J Pediatr Hematol Oncol; 2018 Nov; 40(8):e544-e546. PubMed ID: 28991129
[TBL] [Abstract][Full Text] [Related]
19. Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC.
de Fontbrune FS; Galambrun C; Sirvent A; Huynh A; Faguer S; Nguyen S; Bay JO; Neven B; Moussi J; Simon L; Xhaard A; Resche-Riggon M; O'Meara A; Fremeaux-Bacchi V; Veyradier A; Socié G; Coppo P; de Latour RP
Transplantation; 2015 Sep; 99(9):1953-9. PubMed ID: 25651309
[TBL] [Abstract][Full Text] [Related]
20. Transplantation-Associated Thrombotic Microangiopathy Risk Stratification: Is There a Window of Opportunity to Improve Outcomes?
Jodele S; Dandoy CE; Sabulski A; Koo J; Lane A; Myers KC; Wallace G; Chima RS; Teusink-Cross A; Hirsch R; Ryan TD; Benoit S; Davies SM
Transplant Cell Ther; 2022 Jul; 28(7):392.e1-392.e9. PubMed ID: 35490975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]